The purpose of this research study is to determine whether a new vaccine for typhoid fever is
safe and effective. This study will also look at what effects (good and bad) this new
vaccine, Ty800, has on the volunteers. The study will determine the highest dose of Ty800
that can be given without causing severe side effects. About 54 healthy males and females,
ages 18-45 inclusive, in the Cincinnati metropolitan area will be enrolled in this study.
They will be in the study for approximately 7 months, which includes a one month screening
period, study product administration on Day 0, a 10-day hospital stay, an outpatient period
on Days 9-28 with 4 follow-up visits, and safety follow-up phone calls at 2 and 6 months
after hospital discharge. Researchers hope that this trial will help produce a vaccine that
combines a high level of durable protective immunity with simplicity of administration and
minimal reaction to the vaccine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)